Connect Biopharma Completes Enrollment In Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart As Adjunct To Standard Of Care For Acute Exacerbations In Asthma And Type 2 Inflammation

– On track to also complete enrollment in the Seabreeze STAT COPD study this month –

– Expect to report topline data from Seabreeze STAT Asthma study in early September 2026 –

– Strong balance sheet with cash runway into 2H 2027 –
 

SAN DIEGO, June 17, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced the completion of enrollment in its Phase 2 Seabreeze STAT Asthma study evaluating the safety and efficacy of rademikibart, the Company's next-generation, potentially best-in-class anti-interleukin-4-receptor alpha (IL-4Rα) antibody, as an adjunct to standard of care for acute exacerbations in participants with asthma and type 2 inflammation.

Connect expects to report topline data from the Phase 2 Seabreeze STAT Asthma study of rademikibart for acute exacerbations in early September 2026 followed soon after for the Phase 2 Seabreeze STAT COPD study. The Company plans to move quickly to meet with the U.S. Food and Drug Administration (FDA) to gain alignment on a Phase 3 program later this year.